| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Andrea Giuffrida | |
| Lance R McMahon | |||
| P2860 | cites work | Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain | Q22001491 |
| Cannabis and psychiatric disorders: it is not only addiction | Q22242611 | ||
| Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain | Q24299523 | ||
| Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma | Q24314755 | ||
| Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha | Q24319974 | ||
| The capsaicin receptor: a heat-activated ion channel in the pain pathway | Q24322558 | ||
| Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 | ||
| An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors | Q24534526 | ||
| Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 | ||
| Cannabinoid receptor localization in brain | Q24558751 | ||
| Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects | Q24569799 | ||
| N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase | Q24569817 | ||
| Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | Q24642509 | ||
| GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current | Q24653442 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Anandamide and vanilloid TRPV1 receptors | Q24672354 | ||
| The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin | Q24676808 | ||
| Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids | Q24680497 | ||
| The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects | Q24681369 | ||
| Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism | Q24681426 | ||
| Novel cannabinoid receptors | Q24681482 | ||
| Evidence against the presence of an anandamide transporter | Q24683153 | ||
| Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons | Q28144567 | ||
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Molecular characterization of a phospholipase D generating anandamide and its congeners | Q28186509 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid | Q28204739 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity | Q28241306 | ||
| (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability | Q28244400 | ||
| Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons | Q28245016 | ||
| Endocannabinoids in appetite control and the treatment of obesity | Q28247257 | ||
| A second endogenous cannabinoid that modulates long-term potentiation | Q28248073 | ||
| Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist | Q28262546 | ||
| Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors | Q28265832 | ||
| Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus | Q28268567 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain | Q28281433 | ||
| 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides | Q28295481 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons | Q28363375 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) | Q28376536 | ||
| Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons | Q28573124 | ||
| Molecular composition of the endocannabinoid system at glutamatergic synapses. | Q35220762 | ||
| Δ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication | Q35226616 | ||
| Cannabinoid receptors and endocannabinoids: evidence for new players. | Q35594830 | ||
| The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. | Q35626716 | ||
| Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice | Q36095300 | ||
| Self-administration of cannabinoids by experimental animals and human marijuana smokers | Q36149174 | ||
| Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. | Q36184363 | ||
| The endocannabinoid system: a drug discovery perspective. | Q36207547 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. | Q36251616 | ||
| Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice | Q36370445 | ||
| Evaluation of fatty acid amides in the carrageenan-induced paw edema model | Q36384547 | ||
| Combinatorial roles of nuclear receptors in inflammation and immunity | Q36403404 | ||
| The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition | Q36404693 | ||
| Cannabinoids: a new group of agonists of PPARs | Q36417528 | ||
| Endocannabinoid mechanisms of pain modulation | Q36711160 | ||
| The endocannabinoid system in brain reward processes | Q36741861 | ||
| Biochemistry and pharmacology of endovanilloids | Q36756199 | ||
| Ca(2+)-assisted receptor-driven endocannabinoid release: mechanisms that associate presynaptic and postsynaptic activities | Q36785696 | ||
| Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics | Q36803312 | ||
| PPARs in the brain | Q36849598 | ||
| Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade | Q36902047 | ||
| The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys | Q36926051 | ||
| The endocannabinoid system: emotion, learning and addiction | Q37142237 | ||
| Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats | Q37146387 | ||
| The cannabinoid system in Parkinson's disease: multiple targets to motor effects | Q37146722 | ||
| Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats | Q37224649 | ||
| Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates | Q37239653 | ||
| Endocannabinoid signaling in microglial cells | Q37250243 | ||
| The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses | Q37264865 | ||
| Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia | Q37345438 | ||
| The endogenous cannabinoid system modulates nicotine reward and dependence | Q37353755 | ||
| Targeting CB2 receptors and the endocannabinoid system for the treatment of pain | Q37371095 | ||
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Q44086465 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons | Q44333682 | ||
| Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. | Q44376607 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 | ||
| Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys | Q44492000 | ||
| Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels | Q44524443 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. | Q44702932 | ||
| Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry | Q44733045 | ||
| Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | Q44885114 | ||
| Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia | Q44902561 | ||
| Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity | Q44903331 | ||
| Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice | Q44923318 | ||
| Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality | Q44926848 | ||
| Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus | Q44927481 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. | Q44963304 | ||
| RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol | Q44991723 | ||
| Discriminative stimulus effects of anandamide in rats | Q45084272 | ||
| The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice | Q45087565 | ||
| In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity | Q45096581 | ||
| The biodisposition and metabolism of anandamide in mice | Q45105707 | ||
| The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. | Q45108422 | ||
| Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys | Q45108581 | ||
| Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. | Q45110083 | ||
| Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. | Q45113533 | ||
| The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine | Q45122619 | ||
| Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. | Q45154640 | ||
| Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. | Q45173372 | ||
| Formation of B and T cell subsets require the cannabinoid receptor CB2. | Q46059840 | ||
| Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei | Q46368889 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action | Q34647348 | ||
| Cannabinoid receptors and their ligands | Q34673022 | ||
| Oxidative metabolism of endocannabinoids | Q34673106 | ||
| Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation | Q34743557 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. | Q34807695 | ||
| Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice | Q34846838 | ||
| Transient receptor potential channels: targeting pain at the source | Q34912798 | ||
| Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. | Q35035824 | ||
| Cannabinoids and neuroinflammation | Q35046205 | ||
| Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure | Q35103785 | ||
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 | ||
| Principles of drug abuse liability assessment in laboratory animals | Q35132182 | ||
| Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors | Q35202878 | ||
| Cellular accumulation of anandamide: consensus and controversy | Q35217244 | ||
| A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders | Q81422672 | ||
| Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study | Q81630893 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation | Q37382150 | ||
| The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 | ||
| The therapeutic potential of novel cannabinoid receptors | Q37402927 | ||
| Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells | Q37599138 | ||
| Presynaptic specificity of endocannabinoid signaling in the hippocampus | Q39750122 | ||
| Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. | Q39831177 | ||
| mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. | Q39917016 | ||
| Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? | Q39954666 | ||
| Multiple pathways involved in the biosynthesis of anandamide | Q40106992 | ||
| Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids | Q40146865 | ||
| Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells | Q40158906 | ||
| Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation | Q40403600 | ||
| Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. | Q40449973 | ||
| A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. | Q40528853 | ||
| Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides | Q40702429 | ||
| The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism | Q40817229 | ||
| Role of cyclic AMP in the actions of cannabinoid receptors | Q41090638 | ||
| Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. | Q41093128 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. | Q41713139 | ||
| Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway | Q41791622 | ||
| Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism | Q41940595 | ||
| Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines. | Q41983546 | ||
| A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist | Q42017075 | ||
| The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons | Q42110966 | ||
| Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
| Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. | Q42454049 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain | Q42493166 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum | Q42523780 | ||
| Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats | Q42633348 | ||
| Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease | Q42695373 | ||
| Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats. | Q43334794 | ||
| Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. | Q43355908 | ||
| Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor | Q43503403 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide | Q43608453 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Unawareness of dyskinesias in Parkinson's and Huntington's diseases | Q43696853 | ||
| (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide | Q43703172 | ||
| Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. | Q43742950 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids | Q43830097 | ||
| Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. | Q43833741 | ||
| Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. | Q43873792 | ||
| Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats | Q43893862 | ||
| 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist | Q43961283 | ||
| Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 | ||
| Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo | Q44028862 | ||
| The endogenous cannabinoid system controls extinction of aversive memories | Q44085607 | ||
| Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1 | Q28581167 | ||
| The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum | Q28587112 | ||
| Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol | Q28833498 | ||
| Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro | Q29144178 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 | ||
| Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 | ||
| Animal models of neurological deficits: how relevant is the rat? | Q31091605 | ||
| Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain | Q31570267 | ||
| Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. | Q31711251 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 | ||
| Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. | Q33895436 | ||
| Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol | Q33902321 | ||
| The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors | Q33940288 | ||
| Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses | Q33940688 | ||
| Biology of endocannabinoid synthesis system | Q34015534 | ||
| Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons | Q34023746 | ||
| Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? | Q34098970 | ||
| The validity of the reinstatement model of craving and relapse to drug use. | Q34190646 | ||
| Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis | Q34234907 | ||
| Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice | Q34289368 | ||
| The role of glial cells in Parkinson's disease | Q34318207 | ||
| Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. | Q34320147 | ||
| TRP ion channels in the nervous system. | Q34326647 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. | Q34397288 | ||
| Evidence for novel cannabinoid receptors | Q34415409 | ||
| An endocannabinoid mechanism for stress-induced analgesia. | Q34428429 | ||
| Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs | Q34520933 | ||
| A second fatty acid amide hydrolase with variable distribution among placental mammals | Q34570802 | ||
| Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha | Q34571255 | ||
| Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase | Q34573261 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats | Q46471752 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. | Q46610682 | ||
| Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. | Q46619350 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid typ | Q46801175 | ||
| Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats | Q46819535 | ||
| Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. | Q46852210 | ||
| Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice | Q46920805 | ||
| Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol | Q46943485 | ||
| PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons | Q46949449 | ||
| Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance | Q47893448 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| Cannabinoid receptors and immunity | Q48029970 | ||
| Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture | Q48088888 | ||
| Cannabinoid penetration into mouse brain as determined by ex vivo binding | Q48151733 | ||
| Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. | Q48162553 | ||
| Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 | ||
| Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice | Q48298650 | ||
| The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport | Q48315882 | ||
| Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent | Q48332786 | ||
| Effects of endocannabinoid neurotransmission modulators on brain stimulation reward | Q48428879 | ||
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats | Q48485540 | ||
| Comparative behavioral effects of CNS cholinesterase inhibitors | Q48510079 | ||
| Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. | Q48556515 | ||
| Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. | Q48631827 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. | Q48764465 | ||
| Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one | Q48795983 | ||
| Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia | Q48882619 | ||
| Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system | Q49047040 | ||
| Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal | Q49124925 | ||
| Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. | Q51375099 | ||
| Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 | ||
| Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. | Q52030475 | ||
| Cannabinoid receptors and reward in the rat: a conditioned place preference study. | Q52165794 | ||
| The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. | Q52537508 | ||
| Evolutionary origins of the endocannabinoid system | Q56899189 | ||
| A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats | Q60690596 | ||
| Anandamide – the other side of the coin | Q60690621 | ||
| Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation | Q63363422 | ||
| Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 | ||
| Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain | Q71988975 | ||
| Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist | Q72422733 | ||
| Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? | Q73423096 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine | Q73711457 | ||
| Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist | Q77766471 | ||
| Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 | ||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endocannabinoids | Q10483908 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 90-103 | |
| P577 | publication date | 2009-06-10 | |
| P1433 | published in | Prostaglandins and Other Lipid Mediators | Q15754476 |
| P1476 | title | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability | |
| P478 | volume | 91 |
| Q90582684 | A case series of the dynamics of lipid mediators in patients with sepsis |
| Q34292608 | Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats |
| Q36393644 | Cannabinoids and value-based decision making: implications for neurodegenerative disorders. |
| Q37625769 | Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q64254283 | Structural Insights into CB1 Receptor Biased Signaling |
| Q35119940 | Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. |
Search more.